Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Phase 2

Completed

• Conditions: Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
• Interventions: Drug: Creon IR; Drug: Creon® (DR/GR)

• Registration Number: NCT02415959
• Lead Sponsor: Abbott

Brief Summary

The objective of this study is to assess the efficacy and safety of different doses of Creon Immediate Release (IR) in comparison to Creon® 25,000 Delayed Release/Gastro-Resistant (DR/GR) in subjects with Pancreatic Exocrine Insufficiency (PEI) due to Cystis Fibrosis (CF).

Detailed Description

This study is a Phase II, randomized, parallel-group, active-controlled, double-blind, dose ranging, multicenter study with 4 different doses of Creon IR and one dose of the active control Creon® (DR/GR), administered in subjects of 12 years or older with PEI due to CF.

The study is divided into two periods: a screening period of 14 days and a double-blind treatment period of 6 to 7 days.

Study Timeline

• Study Start: 2015-03
• Study First Submitted: 2015-03-19
• Study First Submitted QC: 2015-04-09
• Study First Posted: 2015-04-14
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Results First Submitted: 2016-01-20
• Results First Submitted QC: 2016-01-20
• Results First Posted: 2016-02-17
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-07
• Last Update Posted: 2016-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Subject has voluntarily signed and dated the Informed Consent Form (ICF). For subjects aged less than 18 years, the parents, or a legally acceptable representative, must sign consent and, as required by the Independent Ethics Committee (IEC), assent will be given by the subject.

2. Subject is 12 years old or older at the time of consent signature.

3. Subject has a diagnosis of CF previously confirmed by:

   • a sweat chloride test > or equal to 60 mmol/Ls and/or
   • two CF causing Cystic Fibrosis trans membrane conductance regulator (CFTR) mutations and
   • CF clinical features

4. Subject has a documented clinically confirmed diagnosis of pancreatic exocrine insufficiency.

5. Subject has human fecal elastase < 100 µg/g stool at screening

6. Subject has PEI that is currently clinically controlled (no clinically overt steatorrhea or diarrhea) under treatment with a commercially available Pancreatic enzyme Replacement Therapy (PERT), on an individually established dose regimen for more than 3 months, with a daily dose not exceeding 10,000 U lipase/kg/day.

7. Females of child-bearing potential and sexually active with men should agree to continue using a medically acceptable method of birth control throughout the study and for 7 days immediately after the last dose of study drug. Medically acceptable methods of birth control include bilateral tubal ligation or the use of either a contraceptive implant, a contraceptive injection (e.g., Depo Provera™), an intrauterine device, or an oral contraceptive taken continually within the past three months and which the subject agrees to continue using during the study or to adopt another birth control method, or a double-barrier method which consists of a combination of any two of the following: diaphragm, cervical cap, condom, or spermicide.

Exclusion Criteria

1. Subject is < 18 years of age and has a Body Mass Index (BMI) Z-Score below -1.5 (minus 1.5)

2. Subject has a history of any of the following gastrointestinal disorders:

   • pancreatitis within 6 months prior to study entry;
   • fibrosing colonopathy;
   • distal ileal obstruction syndrome (DIOS) within 6 months prior to study entry;
   • celiac disease;
   • gastric bypass or partial/total gastrectomy;
   • Crohn's disease;
   • small bowel surgery (other than minor resection due to meconium ileus without resulting in malabsorption syndrome).
   • Any type of malignancy involving the digestive tract in the last 5 years.

3. Subjects with diabetes mellitus, for which the study specific dietary requirements may not be appropriate.

4. Subject has a history of other endocrine or respiratory (except mild asthma) medical illness non-related to CF, which might limit participation in or completion of the study.

5. Subject has a history of any clinically significant neurological, cardiac, renal, hepatic (including Hepatitis B or C), hematologic or psychiatric disease or disorder, or any other uncontrolled medical illness (except cystic fibrosis) which might limit participation in or completion of the study.

6. Subjects requiring concomitant treatment with any medication not allowed by the protocol or is expected to be needed.

7. Subjects requiring Naso-gastric, G-tubes or J-tubes.

8. Subject is currently participating in any other interventional clinical study or has taken any experimental drug within 30 days prior to Screening.

9. Subject is known to be HIV-positive.

10. Subject has a history of allergic reaction or significant sensitivity to pancreatin or inactive ingredients (excipients) of Creon® (DR/GR) or Creon IR

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Creon IR low dose	Creon IR	Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR medium dose	Creon IR	Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon® (DR/GR)	Creon® (DR/GR)	Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR high dose	Creon IR	Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR maximum dose	Creon IR	Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)

Primary Outcome Measures

Name	Time	Method
Coefficient of Fat Absorption (CFA)	End of the 6 to 7 days double-blind treatment period	CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 \[fat intake - fat excretion\] / fat intake

Secondary Outcome Measures

Name	Time	Method
Stool Fat Content	End of the 6 to 7 days double-blind treatment period	Total amount of fat excreted during the stool collection period in grams.
Coefficient of Nitrogen Absorption (CNA)	End of the 6 to 7 days double-blind treatment period	CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 \[nitrogen intake - nitrogen excretion\] / nitrogen intake)
Stool Weight	End of the 6 to 7 days double-blind treatment period	Total amount of stool weight during the collection period in grams

Trial Locations

Locations (17)

Dětská nemocnice FN Brno, Centrum pro cystickou fibrozu; 🇨🇿 Brno, Czech Republic

Klinika nemocí plicních a TBC; 🇨🇿 Brno, Czech Republic

Magyar Imre Kórház; 🇭🇺 Ajka, Hungary

Kenézy Gyula Kórház; 🇭🇺 Debrecen, Hungary

Hospital Vall d ´Hebron; 🇪🇸 Barcelona, Spain

Hospital Universitario de La Princesa; 🇪🇸 Madrid, Spain

Hospital Universitario La Paz; 🇪🇸 Madrid, Spain

Hospital Universitario Virgen del Rocío, Hospital de la Mujer; 🇪🇸 Sevilla, Spain

Hospital Carlos Haya, Hospital Civil, Secretaria de Endocrinologia; 🇪🇸 Málaga, Spain

Hospital La Fé Valencia; 🇪🇸 Valencia, Spain

Kaposi Mór Oktató Kórház; 🇭🇺 Kaposvár, Hungary

Wojewódzki Szpital Specjalistyczny Im M Kopernika W Łodzi; 🇵🇱 Lodzi, Poland

Podkarpacki Ośrodek Pulmonologii i Alergologii; 🇵🇱 Rzeszów, Poland

ENEL-MED Szpital Centrum; 🇵🇱 Warszawa, Poland

Tüdőgyógyintézet Törökbálint; 🇭🇺 Törökbálint, Hungary

Centrum Medyczne Karpacz S.A.; 🇵🇱 Karpacz, Poland

Janusz Stankiewicz Sanatorium ""Cassia-Villa Medica; 🇵🇱 Rabka, Poland